CLINICAL_TRIALS
other
· 2018-05-14
Clinical Trial Update: A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia [Phase 1]
Summary
Phase 1 safety study of SGN-CD123A in patients with Acute Myeloid Leukemia has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Seagen Inc. | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED